White House to announce new drug pricing deals with biotechs: Report

The Trump administration is expected to announce voluntary drug-pricing agreements with midsize biotech companies, requiring discounts for outpatient medicines supplied through Medicaid. The deals would align U.S. prices with those charged abroad, extending efforts that have already involved 17 pharmaceutical firms and could deliver billions of dollars in government savings.